Following detailed consideration of the consultation responses, the Department of Health and Social Care has decided to implement the proposals to maintain broad commercial equivalence with the voluntary scheme, and expedite future consultations, by:
decreasing the statutory scheme headline payment percentage for 2026 and beyond to 16.5%
following an alternative approach to consulting on future adjustments to headline percentage rates by direct engagement through workshops with industry and patient groups, with an invitation to submit written evidence
Proposed changes to the headline payment percentage and consultation procedure of the statutory scheme to control the cost of branded health service medicines.
We are consulting on proposals to amend the Branded Health Service Medicines (Costs) Regulations 2018 to restore broad commercial equivalence with the voluntary scheme for branded medicines pricing, access and growth (VPAG). The consultation will propose to update the payment percentage for newer medicines and simplify the procedure for future consultations.
We welcome responses from any interested person, business or organisation.
Excerpt from the official page. The original is authoritative.